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FoxO transcription factors play critical roles in cell cycle control and cellular stress responses, and abrogation
of FoxO function promotes focus formation by Myc in vitro. Here we show that stable introduction of a
dominant-negative FoxO moiety (dnFoxO) into Eµ-myc transgenic hematopoietic stem cells accelerates
lymphoma development in recipient mice by attenuating Myc-induced apoptosis. When expressed in Eµ-myc;
p53+/− progenitor cells, dnFoxO alleviates the pressure to inactivate the remaining p53 allele in upcoming
lymphomas. Expression of the p53 upstream regulator p19Arf is virtually undetectable in most
dnFoxO-positive Myc-driven lymphomas. We find that FoxO proteins bind to a distinct site within the
Ink4a/Arf locus and activate Arf expression. Moreover, constitutive Myc signaling induces a marked increase
in nuclear FoxO levels and stimulates binding of FoxO proteins to the Arf locus. These data demonstrate that
FoxO factors mediate Myc-induced Arf expression and provide direct genetic evidence for their
tumor-suppressive capacity.
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The FoxO subclass of forkhead-box transcription fac-
tors—consisting of FoxO1 (FKHR), FoxO3a (FKHRL1),
FoxO4 (AFX), and FoxO6—regulates numerous cellular
functions including proliferation, stress sensitivity, and
survival; it has also been implicated in the regulation of
organism life span (for review, see Birkenkamp and Cof-
fer 2003; Accili and Arden 2004; Greer and Brunet 2005).
The members of this family activate gene expression via
interaction with a specific DNA sequence, and known
targets include the cell cycle regulating Kip1 (Medema et
al. 2000), the proapoptotic Bim (Dijkers et al. 2000), the
DNA damage-responsive Gadd45a (Tran et al. 2002), and
the oxidative stress-protective manganese superoxide
dismutase (Kops et al. 2002) genes. In addition, FoxO
proteins can repress several cell cycle promoting genes
(e.g., cyclin D1 and cyclin D2) in a manner that might be
independent of direct DNA binding (Ramaswamy et al.
2002; Bouchard et al. 2004).
In response to growth factor signaling and to oxidative
stress, FoxO proteins are post-translationally modified
by phosphorylation, acetylation, and ubiquitination; col-
lectively, these modifications regulate FoxOs’ subcellu-
lar localization, transcriptional activity, and stability
(Brunet et al. 1999, 2004; Motta et al. 2004; van der Horst
et al. 2006). Notably, all FoxO proteins are inhibited by
protein kinase B/Akt-mediated phosphorylation that
promotes their nuclear export and subsequent proteo-
lytic degradation via ubiquitination by the SCFSkp2 com-
plex (Brunet et al. 1999; Huang et al. 2005). As a conse-
quence, FoxO proteins mediate the induction of p27Kip1
and Bim expression in response to inhibition of the phos-
phatidylinositol-3-OH (PI3)-kinase/Akt pathway (Medema
et al. 2000; Nakamura et al. 2000; Stahl et al. 2002).
Conditional codeletion of the FoxO1, FoxO3, and
FoxO4 alleles uncovers a context-dependent cancer-
prone phenotype characterized by thymic lymphomas
forming in some and hemangiomas developing in most
animals after a long latency (Paik et al. 2007), suggesting
that FoxO proteins exert their tumor-suppressive capa-
bility in the presence of additional oncogenic mutations.
In support of this view, we recently identified Akt-me-
diated phosphorylation of FoxO proteins as the critical
PI3-kinase signaling component that substitutes for on-
cogenic Ras in Myc-induced proliferation and focus for-
mation in vitro (Land et al. 1983; Bouchard et al. 2004).
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Furthermore, constitutive Akt signaling cooperates
with Myc to accelerate B-cell lymphomagenesis (Wendel
et al. 2004); however, it remains unclear whether
Akt-mediated phosphorylation of FoxO proteins contrib-
utes to Eµ-myc transgenic lymphoma formation in this
setting.
Proapoptotic Arf/p53 signaling is known as the pivotal
Myc-induced tumor-suppressive barrier (Sherr 2006),
which, in turn, must be attenuated in full-blown Myc-
driven malignancies (Zindy et al. 1998; Eischen et al.
1999; Bertwistle and Sherr 2006). Eµ-myc transgenic
mice lacking one p53 allele develop lymphomas that in-
activate the remaining wild-type allele (Hsu et al. 1995;
Schmitt et al. 1999). Likewise, Eµ-myc; Arf+/− or Eµ-myc;
Ink4a/Arf+/− mice produce tumors that lack expression
of p19Arf (Eischen et al. 1999; Schmitt et al. 2002a). Pri-
mary Arf deletions protect cells from acquiring p53 mu-
tations during lymphoma development (Eischen et al.
1999; Sherr et al. 2005). Similarly, introduction of
strictly anti-apoptotic genes such as bcl2 or a dominant-
negative form of caspase 9 into Eµ-myc; p53+/− hemato-
poietic stem cells alleviates the pressure to inactivate
p53, thereby underscoring apoptosis as the critical p53-
governed tumor suppressor function in Myc-driven lym-
phomagenesis (Schmitt et al. 2002b).
Previous work has shown that p53 and FoxO3a share
target genes and that FoxO3a can activate transcription
via p53 sites, suggesting a potential collaboration of
FoxO3a and p53 in tumor suppression (Nemoto et al.
2004; You et al. 2006). Although a direct interaction be-
tween FoxO3a and p53 proteins has been demonstrated
under conditions of overexpression (Nemoto et al. 2004),
the observed collaboration would be consistent with an
as-yet-unidentified FoxO target acting upstream of p53.
We report here that FoxO factors elicit their tumor-sup-
pressive potential as critical inducers of Arf during Myc-
driven lymphomagenesis, providing further evidence for
a close link between the FoxO and p53 tumor suppressor
pathways.
Results
FoxO inactivation promotes Myc-driven
lymphomagenesis by disabling p53-mediated
apoptosis
To examine the tumor-suppressive potential of FoxO
transcription factors in vivo, we used a dominant-nega-
tive FoxO allele (dnFoxO) that comprises the conserved
DNA-binding domain of FoxO4. This fragment binds
DNA but is incapable of activating FoxO target genes
due to lack of the transactivation domain, and has been
shown to act as a dominant-negative allele for FoxO
subclass members in several experimental systems
(Medema et al. 2000; van den Heuvel et al. 2005). FoxO-
inactivated Myc-driven B-cell lymphomas were gener-
ated via infection of Eµ-myc transgenic fetal liver cells, a
source of hematopoietic progenitors, with a retrovirus
encoding dnFoxO together with an IRES (internal ribo-
somal entry side)-linked green fluorescent protein (GFP)
and their subsequent propagation in lethally irradiated
recipient mice (Fig. 1A, insert). Extensive microarray
analysis confirmed that these lymphomas expressed
lower mRNAs levels of several FoxO target genes rela-
tive to lymphomas not expressing dnFoxO, confirming
that the introduced dnFoxO moiety exerts a dominant-
negative function in vivo (Supplementary Table 1;
Supplementary Fig. 1). Expression of dnFoxO signifi-
cantly accelerated the development of Eµ-myc lympho-
mas relative to lymphomas forming in animals reconsti-
tuted with empty vector-transduced cells (hereafter re-
ferred to as controls; P < 0.0001) (Fig. 1A). To determine
whether p53-mediated signaling is still selected against
during Myc-driven lymphomagenesis when FoxO func-
tion has been ablated, Eµ-myc; p53+/− fetal liver cells
transduced with retroviruses encoding dnFoxO-IRES-
GFP or GFP-only as a control were propagated in recipi-
ent mice as well. In both groups, lymphoma manifesta-
tion occurred much faster when compared with controls
(both P < 0.0001), but lymphoma latency did not overtly
differ between the two p53+/− groups. As expected,
mock-transduced Eµ-myc; p53+/− fetal liver cells gave
rise to lymphomas that deleted the remaining p53 wild-
type allele (considered p53-null; 10 out of 10 cases tested
by allele-specific genomic PCR for allelic p53 loss) (see
also Schmitt et al. 2002b; three cases are shown in Fig.
1B). In contrast, all GFP-positive dnFoxO-lymphomas re-
tained the remaining p53 allele (15 out of 15 cases tested;
P < 0.0001) (three cases are shown in Fig. 1B). Thus, the
dnFoxO moiety alleviates the selective pressure to inac-
tivate p53 during Eµ-myc-driven lymphomagenesis.
No significant differences could be found regarding the
proliferative capacity of lymphomas with different geno-
types as assessed by Ki67 immunostaining and the fre-
quency of mitotic figures in situ (Fig. 1C). However,
spontaneous apoptosis, visualized by hematoxilin/eosin
staining and quantified by TUNEL (terminal deoxy-
nucleotidyl transferase dUTP nick end labeling), was de-
tectable at significantly higher levels in control lympho-
mas when compared with lymphomas lacking intact p53
alleles or expressing dnFoxO (Fig. 1C). Hence, inactiva-
tion of FoxO family members accelerates Myc-driven
lymphomagenesis primarily by suppressing p53-medi-
ated apoptosis. Given the reduced levels of spontaneous
apoptosis in the presence of p53 alleles in dnFoxO-driven
lymphomas, we next addressed whether p53 is expressed
in these genotypes. Comparable with the demonstration
of p53 transcripts in nine out of nine control lympho-
mas, p53 transcripts remained detectable in seven out of
eight Eµ-myc; p53+/− lymphomas with confirmed expres-
sion of the dnFoxO moiety (Fig. 1D; Supplementary Fig.
2A). In contrast, p53 expression was lost in four out of
four Eµ-myc; p53+/− lymphomas, reflecting the loss of
the second p53 allele (P = 0.0101) (three cases are shown
in Fig. 1B,D). Sequence analysis of exons 4–8, spanning
the DNA-binding domain, of the p53 transcripts present
in two p53+/−; dnFoxO lymphomas (tumors 4 and 5)
failed to uncover mutations, suggesting that the low lev-
els of spontaneous apoptosis in these tumors are not
caused by mutant p53.
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FoxO transcription factors enhance expression of the
proapoptotic Bcl2 family member and BH3-only protein
Bim in certain cell types (Stahl et al. 2002). Moreover,
Bim is an essential mediator of Myc-induced cell death
in B-cell lymphomagenesis (Egle et al. 2004), where Bim
deletion protects against p53 loss (Hemann et al. 2005).
Consequently, repression of Bim in lymphomas express-
ing dnFoxO might explain the observed phenotypes.
However, no overt differences in the expression levels of
the differentially spliced isoforms of Bim were observed
throughout the genotypes (Fig. 2A; Supplementary Fig.
2B). Moreover, Myc levels were unaffected by the dn-
FoxO moiety, thereby excluding the possibility that ab-
lation of FoxO function may allow lymphomas to form
with lower Myc levels, which, in turn, might fail to ac-
tivate p53 (Fig. 2A).
Increased expression of the translation factor eIF4E,
which is released by Akt/mTORC1-mediated phos-
phorylation of 4EBP1 (for review, see Hay and Sonenberg
2004; Guertin and Sabatini 2007), can substitute for
phosphorylation-activated Akt to accelerate Myc-driven
lymphoma formation via suppression of apoptosis (Rug-
gero et al. 2004; Wendel et al. 2004). However, we ob-
served neither reduced levels of 4EBP1 nor increased
amounts of eIF4E transcripts in dnFoxO-lymphomas
compared with lymphomas not carrying the dnFoxO al-
lele (Supplementary Fig. 2C). Furthermore, we used a
panel of antibodies directed against phospho-mTOR,
phospho-Akt, and phospho-4EBP1 together with appro-
priate controls to judge the activity of the Akt/mTOR
pathway throughout the lymphoma panel. There was no
detectable impact of dnFoxO on phosphorylation or ex-
pression levels of any of these proteins, and, in particu-
lar, indistinguishable amounts of eIF4E protein were ob-
served (Supplementary Fig. 2D). Thus, in cooperation
with Myc, FoxO factors control neither directly (as tran-
Figure 1. The dnFoxO moiety accelerates Myc-driven lymphomagenesis by blocking p53-dependent apoptosis. (A) Lymphoma inci-
dence in recipient mice of Eµ-myc; p53+/+ or Eµ-myc; p53+/− hematopoietic stem cells stably transduced with dnFoxO (p53+/+;dnFoxO;
n = 9 [red]; and p53+/−;dnFoxO; n = 15 [purple]) or mock-infected (p53+/+;mock [ctrl.]; n = 12 [black]; and p53+/−;mock [p53-null]; n = 10
[blue]). (Insert) Representative flow cytometric GFP scans of Eµ-myc; p53+/+ fetal liver cells (FLC) infected with the MSCV-dnFoxO-
IRES-GFP retrovirus (top) and of lymphoma cells (LC) arising from this population after stem cell transplantation (percentage reflects
fraction of GFP-positive cells), indicating positive selection of the dnFoxO moiety (bottom). (B) Allele-specific p53 PCR from genomic
DNA extracted from representative p53+/−; dnFoxO (+dnFoxO) and p53+/−; mock (−dnFoxO) lymphoma samples and p53+/+ and p53+/−
MEFs as internal PCR control (normal tissue [N], lymphoma tissue from the same animal [T]). (C) Lymph node histopathology of the
indicated genotypes sampled at lymphoma diagnosis to visualize histomorphology and mitotic figures by hematoxylin/eosin (H&E),
proliferation by Ki67, and spontaneous apoptosis by TUNEL staining in situ, and their respective quantifications. (D) Expression
analysis of p53 and dnFoxO transcripts by RT–PCR in individual lymphomas (n = 3 per genotype) with S16 as a control.
Myc and FoxO in vivo
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scriptional regulators) nor indirectly the activity of the
Akt/mTORC1/4EBP/eIF4E pathway. Notably, our find-
ings do not question the previously reported collabora-
tive role of activated Akt or eIF4E in Myc-driven lym-
phomagenesis (Ruggero et al. 2004; Wendel et al. 2004),
but argue against eIF4E as the critical mediator of FoxO
function in Myc-driven lymphomagenesis.
DnFoxO-driven Myc-lymphomas display reduced
Ink4a/Arf expression levels
Reduced apoptosis despite intact p53 genes has been
demonstrated in Eµ-myc lymphomas harboring Ink4a/
Arf defects (Eischen et al. 1999; Jacobs et al. 1999;
Schmitt et al. 1999). While control lymphomas—except
those that spontaneously selected for a biallelic deletion
at the Ink4a/Arf locus (tumor 7 in Supplementary Fig.
2E)—and p53-null lymphomas express moderate or high
levels of p19Arf and of p16Ink4a, p53-proficient dnFoxO-
lymphomas (tumors 1–5) virtually lacked p19Arf expres-
sion and displayed markedly reduced protein levels of
p16Ink4a (Fig. 2B,C), although no gross deletions at the
gene locus were found in these cases (Supplementary Fig.
2E). Even when comparing only those lymphomas that
retain expression of wild-type p53 (e.g., tumors 2 or 4 vs.
7–9, as verified by sequence analysis), average p19ARF
levels were markedly higher in the absence of dnFoxO,
suggesting a dnFoxO-dependent mechanism of Arf re-
pression beyond the established p53/p19Arf negative
feedback loop (Kamijo et al. 1998). Quantitative real-
time reverse-transcriptase PCR (RQ-PCR) showed that
the reduced expression of p19Arf and p16Ink4a was paral-
leled by lower (but detectable) Arf and Ink4a mRNA lev-
els in lymphomas expressing dnFoxO (Fig. 2D). In addi-
tion, these lymphomas expressed moderately reduced
levels of Ink4b mRNA, consistent with previous obser-
vations that all three genes encoded at the Ink4b/Ink4a/
Arf locus are coregulated in several biological settings
(Gil and Peters 2006). Further analyses showed that these
effects were specific for this locus, since transcript levels
Figure 2. Impact of dnFoxO on critical growth restraints in Eµ-myc transgenic lymphomas arising from a p53+/+ or p53+/− background.
(A) Expression levels of Myc (depicted by arrow) and Bim (extra long [EL], long [L], and short [S] variants) and -actin as a loading control
by immunoblot analysis (three individual lymphomas per genotype). Note that p53+/− lymphomas without dnFoxO are in fact p53-null.
(B) p19Arf and p16Ink4a protein expression (as in A; shown are both a short exposure [short exp.] and a long exposure [long exp.] of the
same blot). (Lane 6) Please note that the only tumor that expresses both dnFoxO and detectable levels of p19Arf has lost p53 expression
(cf. Fig. 1D). (C) Expression analysis of p19Arf and p16Ink4a proteins by immunohistochemistry in representative lymph node sections
of the indicated genotypes. (D) RQ-PCR analyses of the indicated cell cycle inhibitors plotted as relative level of transcript (RLT) in
28 lymphomas with (closed circles; n = 16) and without (open circles; n = 12) the dnFoxO moiety. For each of these groups, the
horizontal line represents the median of the relative expression level.
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of other cell cycle inhibitors, p21Cip1 and p27Kip1, re-
mained unaffected by the dnFoxO moiety in Myc-in-
duced lymphomas (Fig. 2D). Thus, FoxO inactivation
correlates with greatly reduced levels of the Ink4a/Arf gene
products in the context of constitutive Myc expression.
To extend our observation of dnFoxO’s ability to alle-
viate selective pressure against p53 alleles in Myc-driven
lymphomagenesis to the Arf locus, Eµ-myc; Arf+/− fetal
liver cells stably transduced with dnFoxO-IRES-GFP at
∼10% infection efficiency were transplanted into recipi-
ent animals, and upcoming lymphomas were examined
by flow cytometry to identify the GFP-positive subset of
lymphomas that formed with the dnFoxO-IRES-GFP cas-
sette expressed (four out of seven cases). Independent of
their dnFoxO status, lymphomas developed rapidly
within the expected latency (data not shown; cf. Schmitt
et al. 2002a). Importantly, all four dnFoxO-positive Eµ-
myc; Arf+/− lymphomas were found to express virtually
no p19Arf protein in accordance with low but detectable
Arf transcript levels despite a lack of overt genomic de-
fects at the Ink4a/Arf locus (three cases shown in
Supplementary Fig. 3A–C). In contrast, all three GFP-
negative and, hence, dnFoxO-negative Eµ-myc; Arf+/−
lymphomas selected for Ink4a/Arf deletions that ren-
dered them genomically Arf-null (one case shown in
Supplementary Fig. 3A–C). These data and the previous
observation that deletion of Arf, but not of Ink4a, at this
locus cooperates with Myc in lymphoma development
via interrupting oncogenic signaling to p53 (Eischen et
al. 1999; Krimpenfort et al. 2001) strongly suggest that
dnFoxO facilitates Myc-induced lymphomagenesis
through reduction of Arf expression.
Myc-lymphomas expressing the dnFoxO moiety
functionally recapitulate Arf−/− lymphomas
In order to test whether reduction of Arf levels is the
crucial mechanism by which dnFoxO accelerates the for-
mation of p53-proficient Myc-driven lymphomas, we in-
fected cultured control, Arf−/−, and p53-null Eµ-myc
lymphomas cells with retroviruses encoding either GFP
only or the dnFoxO-IRES-GFP moiety. In these experi-
ments, the fraction of GFP-only-infected cells remained
unchanged over time. Consistent with the in vivo obser-
vations, expression of the dnFoxO moiety provided a se-
lective advantage to control lymphomas, leading to a
strong expansion of this subpopulation during the obser-
vation period (Fig. 3A). Importantly, no such expansion
was observed in Arf−/− or p53-null lymphomas, demon-
strating that inactivation of FoxO transcription factors
fails to provide a specific growth advantage in Eµ-myc
lymphomas that lack functional p19Arf or p53. Further-
more, dnFoxO-driven lymphomas, like p19Arf-deficient
lymphomas, displayed a pseudo-diploid DNA content,
while the chromosomally instable p53-deficient lym-
phomas exhibited overt aneuploidy (three out of three
cases tested for each genotype) (data not shown; see also
Eischen et al. 1999; Schmitt et al. 1999).
p19Arf primarily acts via physical binding and degra-
dation of the p53 E3 ubiquitin ligase Mdm2 (Zhang et al.
1998), thereby controlling p53 protein levels indepen-
dent of its activation via post-translational modifica-
tions in response to DNA damage (Kamijo et al. 1999).
Upon exposure to the DNA-damaging anti-cancer agent
adriamycin (ADR), dnFoxO-expressing and Arf−/− lym-
phomas displayed similar levels of p53 activation and
induction of the p53 targets Cip1 and PUMA, encoding a
proapoptotic BH3-only protein (Fig. 3B; Nakano and
Vousden 2001). The induced protein levels were expect-
edly less pronounced when compared with control lym-
phoma cells not expressing the dnFoxO moiety due to
the much lower basal p53 levels in Arf−/− and dnFoxO-
lymphomas. No induction of p21Cip1 or of PUMA could
be detected in ADR-treated p53-null lymphoma cells
(see also Schmitt et al. 1999). To directly test the func-
tionality of this DNA damage-triggered p53 response, we
Figure 3. Inactivation of FoxO transcrip-
tion factors promotes development of Myc-
lymphomas that retain an intact DNA dam-
age response. (A) Relative changes of the
GFP-positive fraction of control, Arf−/−, and
p53-null lymphoma cells 48 h after infection
with either a GFP-only (empty) or a dnFoxO-
IRES-GFP-encoding (dnFoxO) retrovirus; as-
terisk denotes a significant P-value of <0.05.
(B) Representative immunoblot analysis to
detect p53, p21Cip1, and PUMA expression
levels (with -tubulin as a loading control) in
lymphoma cells of the indicated genotypes
exposed to 0.5 µg/mL DNA-damaging agent
ADR for 2 or 4 h or left untreated. (C) Per-
centage of freshly isolated lymphoma cells of
the indicated genotypes trapped in mitosis
(i.e., displaying nuclei with condensed, ho-
mogeneously Hoechst-stained chromo-
somes) after 20 h of exposure to 0.1 µg/mL
mitotic spindle poison nocodazole alone or
applied 2 h after an initial -irradiation of 4 Gy (n = 3 each). (D) Viability analysis by trypan blue dye exclusion of the indicated
lymphoma cell populations exposed in vitro for 24 h to 0.5 µg/mL ADR relative to untreated cells of the same genotypes (n = 3 each).
Myc and FoxO in vivo
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subjected lymphoma cells to a “mitotic trap” assay, in
which p53-proficient cells are expected to arrest in re-
sponse to -irradiation at G1 or G2 checkpoints, while
p53-dysfunctional cells can progress into an M-phase
block set by the spindle poison nocodazole (Bunz et al.
1998; Schmitt et al. 2002b). Indeed, p53-null lymphoma
cells, in contrast to dnFoxO-driven, control, or likewise,
Arf−/− lymphoma cells, failed to properly halt in cycle
prior to the M-phase block, again demonstrating the in-
tegrity and DNA damage responsiveness of the p53 pro-
gram in dnFoxO-lymphomas comparable with Arf−/−
lymphomas (Fig. 3C). Ultimately, we asked whether dn-
FoxO-lymphomas—irrespective of their markedly re-
duced spontaneous apoptotic activity—might still be
susceptible to drug-induced cell death. Although less
sensitive when compared with controls, dnFoxO-lym-
phoma cells died at a significantly higher rate than p53-
null lymphomas following exposure to ADR in a short-
term cytotoxicity assay (P < 0.0003), while the extent of
cell death was indistinguishable between dnFoxO- and
Arf−/− lymphoma cells (Fig. 3D). Therefore, inactivation
of FoxO transcription factors by the dnFoxO moiety pro-
motes early-onset Myc-lymphomas that display func-
tional deficits reminiscent of those detectable in lym-
phomas that formed in the absence of both Arf alleles.
FoxO transcription factors induce Arf expression
To demonstrate that Myc-induced Arf expression de-
pends on FoxO action in cellular settings outside the
lymphoid compartment, we expressed Myc, dnFoxO, or
both in primary mouse embryo fibroblasts (MEFs; in-
fected immediately after plating without further passag-
ing) using retroviral gene transfer (Supplementary Fig.
4A). In line with our previous observation that dnFoxO
strongly enhances colony formation by Myc in MEFs
(Bouchard et al. 2004), coexpression of dnFoxO reduced
induction of p19Arf by Myc, while protein levels of
p16Ink4a and Bim remained unchanged in response to
Myc or dnFoxO action (Fig. 4A). Similar experiments
were carried out in primary B-cells and in hematopoietic
stem cells; however, p19Arf protein levels were ex-
tremely low, and ectopic expression of Myc failed to up-
regulate expression of p19Arf in both cell types in short-
term assays, thereby precluding a robust analysis of the
effects of dnFoxO in these settings (data not shown).
To exclude that the effects observed reflect a gain of
function beyond FoxO inactivation exerted by the dn-
FoxO moiety, we used a p19Arf/p53-proficient MEF-de-
rived 3T3 cell line (hereafter referred to as 3T3 cells)
(Supplementary Fig. 4B; B. Herkert and M. Eilers, un-
publ.) engineered to stably express an inducible FoxO3a
estrogen receptor (ER) fusion protein, in which the Akt-
phosphorylable sites are mutated to alanine residues
(FoxO3aA3-ER) (Supplementary Fig. 4C). The resulting
protein can be activated by addition of 4-hydroxy-
tamoxifen (4-OHT) independently of PI3-kinase or Akt
activity (Tran et al. 2002). Addition of 4-OHT induced
expression of Arf in several independent clones of cells
expressing FoxO3aA3-ER, but not in control 3T3 cells
(Fig. 4B,C; data not shown), demonstrating that activa-
tion of FoxO3a is sufficient to induce expression of
p19Arf. The kinetics of the induction and the magnitude
of the response were similar to those observed for p27Kip1
(Fig. 4B). RQ-PCR analysis revealed that the amounts of
p19Arf protein precisely followed the 4-OHT-dependent
elevation of Arf mRNA levels (Fig. 4B,C). Consistent
with the reported findings in lymphoma cells, activation
of FoxO3a also enhanced expression of Ink4a and Ink4b
transcripts, albeit to a lower extent (Fig. 4C; cf. Fig. 2D).
Importantly, when cycloheximide was added prior to
4-OHT treatment, FoxO3a was still capable of inducing
Arf transcription, demonstrating that no intermediate
protein has to be synthesized to mediate the effects of
FoxO3a on Arf expression (Supplementary Fig. 4D).
Hence, mirroring the inhibitory action of dnFoxO on Arf
expression, acute activation of FoxO3a produces an im-
mediate and substantial increase of Arf mRNA and
p19Arf protein expression.
FoxO transcription factors directly act at the Arf locus
Inspection of the genomic sequence of the murine
Ink4a/Arf locus revealed several potential FoxO-binding
sites (FBS) localized in the first intron of the Arf gene and
in the first intron of the Ink4a gene (Fig. 5A). To deter-
mine whether FoxO proteins bind to these sites in vivo,
we performed chromatin immunoprecipitations (ChIPs)
from 3T3 cells expressing FoxO3aA3-ER before and after
addition of 4-OHT (Fig. 5B). Using either anti-ER or anti-
Figure 4. FoxO transcription factors induce Arf expression. (A)
Immunoblot analyses of p19Arf, p16Ink4a, and Bim levels (using
-actin as a loading control) in pools of primary MEFs infected
with retroviruses expressing Myc, dnFoxO, or both. Cells were
harvested immediately after selection with puromycin (4 d after
infection). (B) Expression of p19Arf, p27Kip1, and -actin as a
loading control by immunoblot analysis in FoxO3aA3-ER cells
following activation of FoxO3aA3 in response to 4-OHT. (C)
RQ-PCR time-course analysis documenting levels (relative to
S16 transcripts) of the indicated mRNAs after FoxO3aA3-ER
activation by addition of 4-OHT.
Bouchard et al.
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FoxO3a antibodies, we detected in vivo binding of
FoxO3a to a single site (FBS2; primer pair 4) in the first
intron of the Arf gene. In contrast, no binding was de-
tected at any of the other potential binding sites or at
several control sites within the Arf locus (illustrated in
Fig. 5A), arguing that the binding is highly specific. This
binding increased profoundly in response to 4-OHT,
further demonstrating that binding at this site is indeed
mediated by the FoxO3aA3-ER protein (Fig. 5B). To
provide direct evidence that the FBS2 site mediates ac-
tivation by FoxO proteins, we cloned an oligonucleotide
spanning 58 nucleotides (nt) surrounding this element in
front of a minimal promoter into a luciferase reporter
plasmid. Transient transfection assays revealed that a
single copy of this element mediated a robust activation
by FoxO3aA3 and a moderate induction by FoxO3a
(Fig. 5C). Furthermore, introduction of six point muta-
tions that disrupt the consensus binding site completely
abolished induction by either FoxO3a or FoxO3aA3
(Fig. 5C). Finally, upon introduction of an oligonucleo-
tide containing six copies of the FBS2-binding sequence
(see Fig. 5A), we observed only a moderately enhanced
activation by FoxO3a and no change in activation
FoxO3aA3, further documenting that a single copy of the
element is fully sufficient to mediate activation by FoxO
proteins (Fig. 5C).
Consistent with a role for FoxO3a protein in mediat-
ing induction of Arf during Myc-driven lymphomagen-
esis, Eµ-myc control lymphomas displayed elevated lev-
els of nuclear FoxO3a relative to nontransgenic lym-
phoid tissue (Fig. 6A). Furthermore, ChIP analyses from
four different lymphomas detected robust binding of en-
dogenous FoxO3a to FBS2 in the Arf locus in each lym-
phoma (primer pair 4 in Fig. 5A); in addition, low, but
significant binding was detected to a second site located
further downstream (FBS4; primer pair 9) (Fig. 6B). Simi-
lar to the results obtained in cells expressing the
FoxO3aA3-ER chimera, no binding of FoxO was detected
at either the Arf or Ink4a promoters (primer pairs 1 and
8) in the lymphoma samples.
Similar to the Arf induction seen upon forced nuclear
expression of FoxO3aA3 (cf. Fig. 4B,C), we found a time-
dependent increase of Arf expression levels in 3T3 cells
engineered to activate an inducible Myc protein (Myc-
ER) after addition of 4-OHT (Fig. 6C). To directly dem-
onstrate that oncogenic Myc signaling renders endog-
enous FoxO3a capable of activating Arf expression, ChIP
analyses were conducted in 3T3 Myc-ER cells. In the
absence of 4-OHT, pharmacological inhibition of PI3-
kinase by addition of LY294002 enhanced binding of en-
dogenous FoxO3a protein to FBS2 in vivo (Fig. 6D). Im-
portantly, activation of Myc-ER by addition of 4-OHT
stimulated binding of endogenous FoxO3a protein to the
same site to a similar extent as addition of LY294002. Of
note, no binding of endogenous FoxO3A was detected to
any other tested site within the Arf locus, confirming the
specificity of binding (Fig. 6D). However, inhibition of
PI3-kinase without activating Myc was insufficient to
induce Arf expression, while other target genes of FoxO
factors such as Kip1 and Bim were activated under these
experimental conditions (Fig. 6E; data not shown). In
conjunction with their ability to induce Arf transcrip-
tion without further protein synthesis, our data show
that FoxO proteins bind to the Ink4a/Arf locus in vivo
Figure 5. FoxO transcription factors bind to the murine Arf
locus and mediate Myc-induced Arf expression. (A, top) Scheme
of the mouse Ink4a/Arf locus, showing the position of the pu-
tative FBS (FBS1–FBS5; stars) and of the primer pairs specific for
the FBS, the control region, and the promoter regions used for
RQ-PCR analysis (dashes 1–10). (Bottom) Alignment of FBS1–
FBS5 with consensus sequences (in bold) of known FoxO targets
and their positions on chromosome 4. (B) ChIP assays docu-
menting in vivo binding of FoxO3aA3-ER proteins to FBS2
within the Ink4a/Arf locus. 3T3 cells expressing the FoxO3aA3-
ER chimera were left unstimulated or induced by addition of
500 nM 4-OHT 6 h prior to ChIP with the indicated antibodies,
followed by RQ-PCR with primer sets specific for FBS1–FBS5
(primer pairs 3, 4, 6, 9, and 10). Plotted are the percentages of
binding based on Ct(FoxO3a [or ER, respectively] IP) − Ct(CT
IP). Please note that the additional control primer pairs shown
in A revealed no binding of FoxO3a to these sites (data not
shown). (C) Luciferase reporter assays of HeLa cells transfected
with CMV-driven expression plasmids encoding wild-type
FoxO3a (FoxO3a wt) or FoxO3aA3 together with luciferase re-
porter plasmids that contain the indicated elements in front of
a minimal promoter derived from the SV40 early promoter.
“FBS2 wt” contains a single copy of a 58mer oligonucleotide
spanning the FBS2 element; “FBS2 mut” carries the same ele-
ment with six point mutations that disrupt the FoxO-binding
sequence (see A, bottom), and “6xFBS2” carries six copies of the
actual FoxO-binding sequence as shown in A.
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and strongly suggest that FoxO proteins directly trans-
activate Arf expression in response to activation of Myc.
Discussion
In this study, we show that disruption of FoxO function
dramatically accelerates Myc-driven lymphomagenesis
by compromising Arf induction, thereby providing evi-
dence for a tumor-suppressive role of FoxO transcription
factors in response to oncogene-initiated tumor develop-
ment in vivo.
Elucidating the role of FoxO transcription factors as
putative tumor suppressors has been difficult due to the
redundant functions of the family members. Recently,
mouse models lacking expression of FoxO1, FoxO3, and
FoxO4 uncovered a predisposition to certain cancers and
benign tumors with a long latency, implying the require-
ment for additional oncogenic lesions to occur (Paik et
al. 2007). Consistent with this view, we report here a
profound and immediate impact of FoxO inactivation on
Myc-driven tumor formation in a mouse model closely
recapitulating the pathogenesis of human Burkitt’s lym-
phoma, which is initiated by a Myc-activating translo-
cation in the vast majority of the cases (Hummel et al.
2006), and in which the Arf/p53 axis represents a par-
ticularly important tumor-suppressive growth con-
Figure 6. Oncogenic Myc signaling acti-
vates FoxO transcription factors. (A)
FoxO3a protein expression by immuno-
blot analysis of lysates from immunobead-
selected splenic nontransgenic B-lympho-
cytes and Eµ-myc transgenic control lym-
phoma cells (n = 2 each) with -tubulin as
a loading control (top), and by immunohis-
tochemistry in representative tissue sec-
tions of nontransgenic wild-type spleen
and Eµ-myc transgenic control lympho-
mas (bottom). (B) ChIP assay of four indi-
vidual Eµ-myc transgenic control lympho-
mas (#1–#4) demonstrating in vivo binding
of endogenous FoxO3a to FBS2 and to a
lesser degree to FBS4. Plotted are the per-
centages of binding based on Ct(FoxO3a
IP) − Ct(CT IP). “Arf prom.” and “Ink4a
prom.” refer to primer pairs 1 and 8 that
span the murine Arf and Ink4a promoters
located at nucleotide positions −431/−376
and −237/−177 relative to the respective
start codons. (C) p19Arf protein induction
by immunoblot analysis with -actin as a
loading control (top) and Arf mRNA in-
duction (relative to S16 transcripts) by RQ-
PCR analysis (bottom) in a time-course ex-
periment conducted in subconfluent Myc-
ER 3T3 cells after 4-OHT addition for the
indicated hours. (D) ChIP assay of Myc-ER
3T3 cells either left untreated, treated
with the PI3-kinase inhibitor LY294002,
or induced with 500 nM 4-OHT followed
by RQ-PCR with the same primer sets as
in B. Plotted are the percentages of binding
based on Ct(FoxO3a IP) − Ct(CT IP). (E)
Time-course immunoblot analyses of
FoxO3a, phospho-Akt [p-Akt(Ser473)],
p19Arf, p27Kip1, and Cdk2 (as a loading con-
trol) protein expression levels (left), and
RQ-PCR analysis (relative to S16 tran-
scripts) documenting Arf and Kip1 mRNA
levels (right) in subconfluent 3T3 cells af-
ter LY294002 addition for the indicated
hours.
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straint (Lindstrom et al. 2001). Our approach identifies
transcriptional activation of Arf as the functionally criti-
cal node linking Myc and FoxO action. Regulation of Arf
expression by FoxO proteins was detectable both in a
loss-of-function (i.e., expressing the dnFoxO moiety) set-
ting under constitutive Myc expression in the lymphoid
compartment in vivo and was confirmed by a gain-of-
function (i.e., the inducible FoxO3aA3 activity) approach
in fibroblasts in vitro.
Importantly, lymphomas arising in the presence of a
dnFoxO moiety retain functional p53 and remain respon-
sive to DNA damage. We suggest, therefore, that FoxO
factors act in a specific pathway that mediates activation
of p53 via p19Arf in response to oncogenic stress, but
have little or no role in regulating p53 function in re-
sponse to DNA damage. Our data also provide a poten-
tial mechanistic link to recent elegant work from several
laboratories using conditional alleles of p53, demonstrat-
ing that restoration of p53 in established tumors induces
tumor regression in a manner that depends on p19Arf, but
not on the presence of acute DNA damage (Martins et al.
2006; Ventura et al. 2007). In this view, FoxO proteins
serve as cofactors that regulate expression of the Ink4a/
Arf locus in response to specific oncogenic signals, but
barely affect p53 function per se, similar to, for example,
Dmp1, which mediates activation of Arf in response to
deregulated MAP kinase activity (Inoue et al. 2000;
Sreeramaneni et al. 2005). However, FoxO proteins differ
from other known Ink4a/Arf regulators such as Dmp1 in
that inhibition of their function does not abrogate cellu-
lar senescence in primary MEFs, and has little impact on
Arf induction in response to oncogenic Ras (V. Paulus-
Hock and M. Eilers, unpubl.). Therefore, our findings im-
ply that FoxO factors activate Arf expression in response
to a physiological stimulus that is distinct from deregu-
lated Ras or MAP kinase activity.
Our data show that FoxO proteins have an instructive
role in regulating Arf expression during Myc-induced
lymphomagenesis. Myc-driven B-cell lymphomas may
present with elevated nuclear FoxO3a levels at diagno-
sis, and mere constitutive expression of nucleus-retained
FoxO3aA3 in tissue culture is sufficient to induce Arf
expression. How FoxO proteins exactly “sense” activa-
tion of Myc to activate Arf remains open at present.
Since PI3-kinase/Akt signaling negatively regulates
FoxO function, one possibility would be a Myc-induced
drop in PI3-kinase activity. Indeed, inhibition of PI3-ki-
nase, like activation of Myc, promotes loading of endog-
enous FoxO to the Arf locus. However, inhibition of PI3-
kinase without activating Myc does not license induc-
tion of Arf, despite the fact that other target genes of
FoxO factors are activated by PI3-kinase inhibition only.
Therefore, additional Myc-induced signals, potentially
including Myc-induced oxidative stress (Vafa et al. 2002),
must exist that license the relatively low amounts of
endogenous FoxO factors to activate expression of Arf,
although p19Arf levels that increased upon Myc activa-
tion in Myc-ER-MEFs exposed to 4-OHT remain unaf-
fected when cotreated with N-acetylcysteine to scavenge
oxygen radicals (Reimann et al. 2007). The identification
of FoxO proteins as critical mediators of Myc-induced
Arf expression will now allow a systematic analysis of
such signals.
Our observations may also have important ramifica-
tions for the clinical use of mTORC1 inhibitors such as
rapamycin as anti-cancer agents with the intention to
target elevated or constitutive PI3-kinase/Akt signaling,
a very common finding in various cancer entities (Viv-
anco and Sawyers 2002). While rapamycin was shown to
inhibit cell cycle progression (Fingar et al. 2004), it was
recently noted that it may lead to elevated Akt activity
(Skeen et al. 2006). Certainly, inhibition of the mTOR
pathway will limit tumor cell proliferation in many can-
cer types and has been shown to reverse chemoresistance
to ADR in Akt-driven Eµ-myc transgenic mouse lym-
phomas in vivo (Wendel et al. 2004), but enhanced inac-
tivation of the tumor-suppressive FoxO transcription
factors via elevated Akt activity as a potentially pro-on-
cogenic side effect of rapamycin warrants further eluci-
dation, particularly since rapamycin is in clinical long-
term use as an immunosuppressant in nonmalignant dis-
ease settings. In this regard, novel therapeutic strategies
combining mTOR with PI3-kinase inhibition (Sun et al.
2005), which may exert their efficacy, at least in part, by
blocking FoxO inactivation as well, might be a particu-
larly safe choice of targeting constitutive PI3-kinase/Akt
signaling in cancer.
Materials and methods
Mice, fetal liver cell transplantation, and assessment
of lymphoma growth
As a source of primary lymphomas or fetal liver cells with de-
fined genetic lesions, Eµ-myc transgenic mice (Adams et al.
1985) were intercrossed to mice harboring targeted deletions at
the p53 (Jacks et al. 1992) or Arf (Kamijo et al. 1997) locus. All
animals were bred in a pure C57BL/6 strain background. Fetal
liver cells were retrovirally transduced in vitro (see below) and
subsequently transplanted into lethally irradiated, nontrans-
genic wild-type mice (Schmitt et al. 2002b). Monitoring of
lymph nodes, processing and fixation of tissues, and isolation of
lymphoma cells were performed as described (Schmitt et al.
2002a; Braig et al. 2005). Apoptosis-related DNA fragmentation
was visualized in situ using a fluorescence-based TUNEL assay
(Roche) with DAPI (4,6-diamidino-2-phenylindole) as a nuclear
counterstain for quantification. DNA content was measured af-
ter propidium iodide staining in a flow cytometer (Schmitt et al.
1999). Proliferation was assessed as the relative frequency of
cells with mitotic nuclear morphology in situ (Schmitt et al.
1999). For quantification, at least 200 cells were counted per
section, and at least three independent samples per genotype
were evaluated.
Cells and in vitro treatments
Primary lymphoma cells and fetal liver cells were cultured as
reported (Schmitt et al. 1999, 2002b). Wild-type primary MEFs
were isolated from embryonic day 13.5 (E13.5) embryos and
cultured in DMEM medium containing 10% fetal calf serum
(FCS; Sigma), 2 mM L-glutamine, 100 U/mL penicillin/strepto-
mycin (GIBCO), and 50 µM -mercaptoethanol (Roth). Mouse
3T3 fibroblasts were derived from MEFs subjected to a 3T3 pro-
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tocol (Todaro and Green 1963). For time-course experiments,
subconfluent mouse 3T3 FoxO3aA3-ER cells or 3T3 Myc-ER
were incubated with 500 nM 4-OHT (Sigma) for the indicated
times. Where stated, 50 µg/mL cycloheximide (CHX; Sigma) or
a solvent control were added to the cells 10 min prior to the
4-OHT treatment (Bouchard et al. 2001). In short-term cytotox-
icity assays, cell viability was analyzed by trypan blue dye ex-
clusion after exposure to the DNA-damaging topoisomerase II
inhibitor ADR (alias doxorubicin; Sigma) at various concentra-
tions for 24 h (Schmitt et al. 1999). The “mitotic trap” assay was
carried out 20 h after the addition of 0.1 µg/mL nocodazole
(Fluka) and, in some experiments, with a 4-Gy -irradiation pre-
ceding nocodazole by 2 h (Bunz et al. 1998; Schmitt et al. 2002b).
At least 200 cells were evaluated for mitotic nuclear morphol-
ogy per lymphoma preparation, and at least three independent
preparations were analyzed per genotype.
Plasmids and retroviral infections
For cloning of an estrogen-inducible allele of human FoxO3aA3
into the retroviral vector pBabe-puro (pBabe-FoxO3aA3-ER-
puro), a 2-kb BamHI fragment of the human FoxO3aA3 was
isolated from the previously described pBabe-FoxO3aA3-puro
(Bouchard et al. 2004) and inserted into BamHI-digested pBabe-
Myc-ER-puro. pBabe-HA-dnFoxO-puro has been described be-
fore (Medema et al. 2000) and was used to shuttle the dnFoxO
fragment into the murine stem cell (retro-)virus MSCV-IRES-
GFP (itself serving as the empty control vector), coexpressing
GFP via an internal ribosomal entry site (MSCV-dnFoxO-IRES-
GFP). Retroviral supernatants were generated by transient
transfections of Phoenix cells and were used to transduce MEFs,
3T3 cells, and Eµ-myc transgenic fetal liver cells (Schmitt et al.
2002b). Infected cells were selected with 2 µg/mL puromycin
(InvivoGen) and 80 µg/mL hygromycin (Calbiochem). Fetal liver
cell populations infected with GFP-coencoding MSCV retrovi-
ruses were transplanted without further selection. For enrich-
ment experiments based on GFP-coexpressing vectors, freshly
infected lymphoma cells were adjusted to ∼15% GFP-positive
cells by admixing uninfected cells of the same lymphoma popu-
lation, and relative changes of the fractions of GFP-positive cells
were reassessed by flow cytometry after 48 h in culture.
RT–PCR, RQ-PCR, and genomic PCR
Two micrograms of total RNA isolated with the peqGOLD Tri-
Fast reagent (Peqlab) were transcribed into cDNA using Mo-
MuLV reverse transcriptase and random primers. Standard PCR
experiments were performed with RedTaq polymerase and spe-
cific primers for mouse p53, dnFoxO-IRES, HA-dnFoxO, hu-
man Myc, and s16. RQ-PCR experiments were performed on an
Mx3000p thermo cycler (Stratagene), with the Hot Gold Star kit
(Eurogentec) and specific primers for mouse Arf, Ink4a, Ink4b,
Cip1, Kip1, Bim, eIF4E, 4EBP1, and s16. Data were plotted as
Ct values (the difference in cycle numbers at which the fluo-
rescence threshold was crossed) relative to a control mRNA
(encoding the ribosomal protein s16) or as relative level of tran-
script (RLT) based on 2(−Ct). Primer sequences are available on
request. RT–PCR products of p53 exons 4–8 were sequenced as
described (Schmitt et al. 1999).
ChIP
Cells expressing FoxO3aA3-ER or Myc-ER were stimulated by
addition of 500 nM 4-OHT, 50 µM LY294002 (Calbiochem), or
a solvent control. After 6 h, cells were harvested and processed
for ChIP. Primary lymphoma cells were expanded, harvested,
and subjected to ChIP analyses. ChIP assays were performed as
described (Bouchard et al. 2001) using the polyclonal rabbit anti-
ER (M-20; sc-542; Santa Cruz Biotechnology), anti-FoxO3a (H-
144; sc-11351; Santa Cruz Biotechnology; no cross-reactivity
with other FoxOs), and control (CT) IgG (Sigma) antibodies.
Immunoprecipitated DNA samples and inputs were PCR-am-
plified and quantified with primer pairs specific for the potential
FBS (FBS1–FBS5; primer pairs 3, 4, 6, 9, and 10), for promoter
regions (primer pairs 1 and 8) (Bracken et al. 2007), and for con-
trol regions (primer pairs 2, 5, and 7) of the murine Ink4a/Arf
locus. For each antibody, the percentage of binding was calcu-
lated based on Ct(relevant IP) − Ct(CT IP), where Ct were
obtained from the input samples as a reference (Nelson et al.
2006). Primer sequences are available on request.
Microarray analyses
Expression analysis was performed on RNA isolated from indi-
vidual lymphomas using a 22.5 K mouse cDNA array. Details




For immunoblotting, cells were lysed by three rounds of freez-
ing and thawing in a buffer containing 50 mM Tris (pH 8), 150
mM NaCl, 1% NP-40, and a cocktail of protease inhibitors
(Sigma). Immunoblotting has been described previously (Steiner
et al. 1995). For immunohistochemical analysis (of three to five
mice examined per genotype), formalin-fixed and paraffin-em-
bedded sections of lymph nodes and spleens were stained ac-
cording to published procedures or manufacturers’ recommen-
dations (Schmitt et al. 1999; Braig et al. 2005). For immunofluo-
rescence, cells were fixed in 2% paraformaldehyde/PBS and
permeabilized in 0.2% Triton-X/PBS before application of anti-
bodies as described (Reimann et al. 2007). The antibodies used
to detect the following antigens were -actin (A5441; Sigma);
p19Arf (R562 and ab80; Abcam); p16Ink4a (sc-1207 and F-12;
Santa Cruz Biotechology); p21Cip1 (sc-397; Santa Cruz Biotech-
nology); p27Kip1 (K25020; Transduction Laboratories); p53
(CM5; Novocastra); PUMA (ab9645; Abcam); Akt (9272), phos-
pho-Ser473-Akt (9271), mTOR (2972), phospho-Ser2481-mTOR
(2974), Raptor (4978), 4EBP1 (9452), phospho-Thr70-4EBP1
(9455), and eIF4E (9742) (all: Cell Signaling Technology); Bim
(AAP-30; Stressgen; and ab15184; Abcam); Cdk2 (sc-163; Santa
Cruz Biotechnology); ER (sc-542; Santa Cruz Biotechnology);
FoxO3a (F2178; Sigma); Ki67 (Tec-3; Dako); Myc (9E10; Upstate
Biotechnology; and sc-764; Santa Cruz Biotechnology); and
-tubulin (T5168; Sigma).
Statistical evaluation
Tumor onset data reflect the time between transplantation of
fetal liver cells and first-time palpability of enlarged lymph
nodes in recipient mice. Statistical comparison of Kaplan-Meier
curves is based on the log-rank test; the unpaired t-test was
applied for comparisons of means and standard deviations, and
the Fisher’s exact test was used to statistically compare cat-
egorical variables (SD; asterisk denoting a significant P-value of
<0.05). All error bars shown denote the SD.
Luciferase assay
Oligonucleotides were annealed and ligated into an XmaI/BglII-
digested pGL2-promoter vector (Promega). The FBS2 wt se-
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quence (5-ccgggggttaatactttctatatcactgacTTTGTTTGCttctgga
cttaggagcaaacatacc-3) contains 58 nt surrounding the 9-base-
pair (bp) consensus sequence (FBS2); FBS2 mut (5-ccgggggttaatac
tttctatatcactgacTTGTCGACCttctggacttaggagcaaacatacc-3) com-
prises the 58mer sequence with a disrupted FBS; and 6xFBS2
(5-ccgggTTTGTTTGCTTTGTTTGCTTTGTTTGCTTTGTT
TGCTTTGTTTGCTTTGTTTGCc-3) contains six times the
9-bp sequence that matches the FoxO consensus binding se-
quence. Transfections of HeLa cells were carried out in tripli-
cate in six-well dishes containing 250,000 cells per well. Cells
were transfected by using CaPO4 with 2 µg of the respective
reporter (pGL2-promoter-empty, -FBS2 wt, -FBS2 mut, or
-6xFBS2) plus 1 µg of pcDNA3.1-empty or pECE-FoxO3a wt or
pcDNA3.1-FoxO3aA3. In each transfection, 100 ng of CMV-
lacZ were transfected to normalize different transfection effi-
ciencies. The total amount of DNA was kept constant in each
transfection by adding equal amounts of expression plasmids.
Cells were harvested after 30 h, and luciferase assays were per-
formed as described previously (Bouchard et al. 1999).
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